Creatine added to resistance training may improve some strength measures—not longevity

The bottom line

A 2017 meta-analysis of 22 randomized trials found that creatine added to resistance training increased DXA lean tissue by 1.37 kg (95% CI 0.97–1.76) and produced small additional gains in chest- and leg-press strength. The trials lasted 7–52 weeks and their mean participant ages ranged from 57 to 70.

A one-year analysis in 38 older men found no added creatine benefit for bone measures, lean tissue, muscle thickness or strength. The evidence is about a supplement-plus-training combination—not creatine as an independent anti-aging treatment.

Why this matters

Maintaining strength and function matters with age, but “lean mass,” maximal gym strength, daily physical function, falls, disability, cognition and lifespan are different outcomes. Creatine marketing often crosses those boundaries faster than the trials do.

What researchers did

The meta-analysis pooled placebo-controlled studies in which both groups performed resistance training, usually two or three times weekly. A registered Canadian study enrolled 90 adults aged 50 or older; published one-year analyses compared creatine and placebo during the same supervised whole-body training program.

What they found

Pooled standardized strength differences were 0.35 for chest press and 0.24 for leg press—modest averages with variation across trials. A 70-person one-year imaging report found selected differences in tibial bone area and lower-leg muscle density, not fewer fractures or better daily function. In the 38-man analysis, both groups changed similarly across bone, muscle and strength measures; adverse events did not differ.

How strong is the evidence?

The pooled signal is more credible than one small positive study, but it combines different regimens, durations and populations. Resistance training was present in both arms, so it is the foundation of the comparison. DXA lean tissue includes water and other nonfat tissue; an increase does not by itself prove new contractile muscle or improved mobility.

What this evidence does not show

It does not show that creatine alone preserves independence, prevents falls or fractures, improves cognition, extends healthspan, reduces mortality or lengthens life. The featured trials do not establish safety for people with kidney disease, complex medication use or frailty, and they do not justify a personal dose or product choice.

Safety and conflicts

The registered one-year study excluded people with pre-existing kidney abnormalities and monitored kidney and liver markers. That design limits generalization to excluded populations. The FDA does not approve dietary supplements for safety and effectiveness before marketing. The meta-analysis authors reported no conflicts; exact funding and product-supply language for the featured one-year reports was not available in the primary abstract/registry metadata checked for this article.

What happens next

Larger, independently funded trials should separate creatine alone from creatine plus well-described training and measure strength, gait, chair rise, falls, disability, quality of life and adverse events over longer periods. Product identity and funding should be reported consistently.